COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable inTrahepatic Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The study is a multicenter phase II randomized trial. The purpose is to investigate both the
efficacy and safety of radiotherapy combined with anti-PD-1 antibody and chemotherapy
(gemcitabine+cisplatin) in unresectable intrahepatic cholangiocarcinoma patients.